Table 3.
Estimates of Post-AMI Drug Adherence by LIS Status and Benefit Phase
| Benefit Phase and LIS Status | N | Mean Months in Phase | Drug Class | |||
|---|---|---|---|---|---|---|
| ACE-inhibitors/ARBs | Beta-blockers | Statins | Clopidogrel | |||
| Mean PDC | Mean PDC | Mean PDC | Mean PDC | |||
| Panel 1: Enrollees with exposure to both the initial coverage and gap phases | ||||||
| Non-LIS | ||||||
| Gap phase months | 2,601 | 7 | 50.9 | 43.3 | 52.9 | 45.9 |
| Initial coverage phase months | 2,601 | 13 | 50.9 | 43.9 | 53.8 | 46 |
| 1st difference | −6.1* | 0 | −0.6 | −0.9 | −0.1 | |
| LIS | ||||||
| Gap phase months | 3,201 | 7.4 | 50.9 | 45.4 | 53.1 | 43.4 |
| Initial coverage phase months | 3,201 | 9.8 | 48.4 | 43.4 | 49.8 | 40.4 |
| 1st difference | −2.5* | 2.5* | 2.0* | 3.3* | 3.0* | |
| DID results | −3.6* | −2.6* | −2.6* | −4.2* | −3.2* | |
| Panel 2: Enrollees with exposure to both the gap and catastrophic phases | ||||||
| Non-LIS | ||||||
| Catastrophic phase months | 466 | 4.6 | 56.7 | 45.4 | 61.6 | 53.7 |
| Gap phase months | 466 | 9.5 | 53.9 | 45 | 59.5 | 51.5 |
| 1st difference | −4.9* | 2.8 | 0.4 | 2.2 | 2.1 | |
| LIS | ||||||
| Catastrophic phase months | 1,564 | 6.2 | 53.2 | 48.7 | 57.7 | 48.6 |
| Gap phase months | 1,564 | 8.4 | 51.9 | 47.1 | 54.7 | 46.9 |
| 1st difference | −2.2* | 1.3 | 1.6 | 3.0* | 1.7 | |
| DID results | −2.7* | 1.5 | −1.2 | −0.8 | 0.4 | |
*
Difference significant at p < .05.